dose 3: Clinical Trials

3 trials of dose 3, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 completed, 1 active not recruiting. 3 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 13Completed 2, Active not recruiting 1

Follow dose 3: new trials by email Literature Review of dose 3 trials Research Report on dose 3

Trials (filtered) newest first · largest first

All 3 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Safety, Tolerability and Pharmacokinetics of ETD-001 Gel
Dose 1, dose 2, dose 3 - Safety Issues
Phase 1CompletedEtern Therapeutics Wuxi Limited562026-03-162026-09-10
Evaluation of Soy-protein Russian Tarragon (Artemisia Dracunculus L.)
Dose 1, Dose 2, Dose 0 - Diabetes Prevention
Phase 1CompletedPennington Biomedical Research Center642014-02-012019-03-21
Transfer of Genetically Engineered Lymphocytes in Melanoma Patients
Dose 1, Dose 2, Dose 3 - Melanoma
Phase 1Active not recruitingLoyola University142012-07-012020-10-30

Conditions studied

Melanoma (1)

Sponsors

Etern Therapeutics Wuxi Limited (1)  ·  Loyola University (1)  ·  Pennington Biomedical Research Center (1)

Countries

United States (2)  ·  China (1)

Top investigators

Jennifer C Rood, Ph.D. (1)  ·  Michael Nishimura, PhD (1)

NIH funding

P01CA154778 (1), P50AT002776 (1), R44CA126461 (1)